Search

Integrating artificial intelligence (AI) into yoga therapy represents a transformative paradigm shift in holistic health management. This article explores the evolving landscape of AI in yoga therapy, encompassing recent advancements, potential applications, ethical considerations, and implications for well-being. Recent advancements in AI have enabled real-time monitoring and personalized interventions during yoga practice, offering unprecedented customization and efficacy. AI-powered virtual assistants and telehealth platforms extend the reach of yoga therapy interventions, enhancing accessibility and inclusivity. However, ethical considerations surrounding privacy, autonomy, equity, transparency, and cultural sensitivity must be carefully addressed to ensure responsible deployment and safeguard the well-being of individuals. By prioritizing ethical principles and values, stakeholders can harness AI's transformative potential to advance the yoga therapy field and promote holistic well-being for individuals and communities worldwide. [ABSTRACT FROM AUTHOR]

Chemical pesticide residues have negative consequences for human health and the environment. Prioritizing a detection method that is both reliable and efficient is essential. Our innovative research explored the application of biosensors based on carbon quantum dots (CQDs) derived from waste tea to detect commonly used pesticides in tea. CQDs have been synthesized using a simple one-pot hydrothermal approach and thoroughly characterized using advanced techniques such as high-resolution transmission electron microscopy, ultraviolet-visible spectroscopy, photoluminescence (PL) spectroscopy, Raman spectroscopy, X-ray diffraction, atomic force microscopy, and X-ray photoelectron spectroscopy. The fluorescence resonance energy transfer-based fluorescence "turn on-off" mechanism has been successfully employed to study the detection of four different pesticides, viz., quinalphos 25 EC, thiamethoxam 25 WG, propargite 57 EC, and hexaconazole 5 EC. The detection limits for quinalphos 25 EC, thiamethoxam 25 WG, and propargite 57 EC were determined to be 0.2, 1, and 10 ng/mL, respectively. Notably, these values are significantly lower than the maximum residue level for each pesticide. We achieved a strong linear correlation ( R = -0.96) with a detection limit of 0.2 ng/mL for quinalphos 25 EC. The quantum yield was determined to be 40.05%. Our research demonstrates that the developed nanobiosensor reliably and accurately detects pesticides, including those present in experimental samples containing mixtures of pesticides., Competing Interests: The authors declare no competing financial interest., (© 2024 The Authors. Published by American Chemical Society.)

Background: A granulocyte colony-stimulating factor, pegfilgrastim, is efficacious though expensive for prophylactic treatment of chemotherapy-induced neutropenia and febrile neutropenia. Biologics available and accessible today, having acceptable safety-efficacy profiles, require postapproval studies for better understanding of such drugs in clinical settings., Aim: This postmarketing surveillance study evaluated the safety of prophylactic Peg-grafeel ™ (pegfilgrastim) in cancer patients with chemotherapy-induced neutropenia., Settings and Design: This prospective, noninterventional, single-arm, open-label study was conducted at 10 study sites in India., Methods: Patients received subcutaneous 6 mg Peg-grafeel ™ approximately 24 h following chemotherapy as part of routine patient care., Statistical Analysis: Data were summarized descriptively., Results: The study included 250 patients (male: female = 36.4%:63.6%; median age, 54 [16-80] years). Most patients had Stage III (33.2%) or IV (41.6%) cancers and received cyclophosphamide (37.2%) and doxorubicin (31.6%) as chemotherapy. On an average, 4 Peg-grafeel ™ doses were administered per patient. Treatment-emergent adverse events (AEs) were reported in 115 (46%) patients, the most common being vomiting (11.6%), pain (11.2%), nausea (8.4%), and constipation (8.4%). Peg-grafeel ™ -related AEs included pain (3.2%), asthenia (2.4%), and arthralgia (1.2%). Bone pain (0.4%) and extremity pain (1.2%) were rare. Grade 3/4 neutropenia and febrile neutropenia occurred in 4 (1.6%) and 3 (1.2%) patients, respectively. Serious AEs included vomiting (2.8%) and pyrexia (2%). No new safety concerns were identified. None of the five deaths was considered related to Peg-grafeel ™ ., Conclusion: The overall safety profile of Peg-grafeel ™ was consistent with the expected safety profile of pegfilgrastim in patients with advanced malignancies in a clinical setting., Competing Interests: Ramkumar Anupama received consultancy fees from Dr. Reddy's Laboratories Ltd. Sinha Nitu is an employee of the study sponsor company, Dr. Reddy's Laboratories Ltd. Nirni Sharanabasappa, Talwar Vineet and Mallavarapu Krishna Mohan have no conflicts to declare.